

*Date:* January 12, 2023.

*Time:* 12:00 P.M. TO 3:00 P.M.

*Agenda:* To review and evaluate contract proposals.

*Place:* National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases,

Democracy II,

6707 Democracy Blvd.,

Bethesda, MD 20892

(Virtual Meeting).

*Contact Person:* Michele L. Barnard, Ph.D.,

Scientific Review Officer,

Review Branch, DEA, NIDDK,

National Institutes of Health,

Room 7353, 6707 Democracy Boulevard,

Bethesda, MD 20892–2542,

(301) 594–8898,

[barnardm@extra.nidk.nih.gov](mailto:barnardm@extra.nidk.nih.gov).

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Dated: December 23, 2022.

**Miguelina Perez,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2022–28358 Filed 12–28–22; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Board of Scientific Counselors, NIDDK.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public as indicated below in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual grant applications conducted by the National Institute of Diabetes and Digestive and Kidney Diseases, including consideration of personnel

qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Board of Scientific Counselors, NIDDK.

*Date:* October 12–13, 2023.

*Open:* October 12, 2023, 10:00 a.m. to 10:20 a.m.

*Agenda:* Introductions and Overview.

*Place:* National Institutes of Health, Building 10, 10 Center Drive, Bethesda, MD 20892 (Virtual Meeting).

*Closed:* October 12, 2023, 10:20 a.m. to 5:40 p.m.

*Agenda:* To review and evaluate to review and evaluate to review and evaluate to review and evaluate personal qualifications and performance, and competence of individual investigators.

*Place:* National Institutes of Health, Building 10, 10 Center Drive, Bethesda, MD 20892 (Virtual Meeting).

*Closed:* October 13, 2023, 10:00 a.m. to 3:10 p.m.

*Agenda:* To review and evaluate to review and evaluate to review and evaluate to review and evaluate personal qualifications and performance, and competence of individual investigators.

*Place:* National Institutes of Health, Building 10, 10 Center Drive, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Michael W. Krause, Ph.D., Scientific Director, NIDDK, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Health, Building 5, Room B104, Bethesda, MD 20892–1818, (301) 402–4633, [mwkrause@helix.nih.gov](mailto:mwkrause@helix.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Dated: December 23, 2022.

**Miguelina Perez,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2022–28373 Filed 12–28–22; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of an Exclusive Patent License: Development and Commercialization of Engineered Cell Therapies for the Treatment of Cancer

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and

Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to Affini-T Therapeutics, Inc. (“Affini-T”), headquartered in Watertown, MA.

**DATES:** Only written comments and/or applications for a license which are received by the National Cancer Institute’s Technology Transfer Center on or before January 13, 2023 will be considered.

**ADDRESSES:** Requests for copies of the patent applications, inquiries, and comments relating to the contemplated Exclusive Patent License should be directed to: Andrew Burke, Ph.D., Senior Technology Transfer Manager, NCI Technology Transfer Center, Telephone: (240)–276–5484; Email: [andy.burke@nih.gov](mailto:andy.burke@nih.gov).

#### SUPPLEMENTARY INFORMATION:

##### Intellectual Property

1. United States Provisional Patent Application No. 63/185,805 filed May 7, 2021, entitled “T Cell Receptors Recognizing C135Y, R175H or M237I Mutation in P53” [HHS Reference No. E–101–2021–0–US–01]; and

2. PCT Application No. PCT/US2022/028066 filed May 6, 2022, entitled “T Cell Receptors Recognizing C135Y, R175H or M237I Mutation in P53” [HHS Reference No. E–101–2021–0–PCT–02].

The patent rights in these inventions have been assigned and/or exclusively licensed to the government of the United States of America.

The prospective exclusive license territory may be worldwide, and the field of use may be limited to the following:

“Development, manufacture and commercialization of T or Natural Killer cell therapy products genetically engineered to express the P53 R175H-reactive T cell receptor claimed in the Licensed Patent Rights for the treatment of cancer in humans.”

E–101–2021 patent family is primarily directed to isolated TCRs reactive to certain mutated forms of tumor protein 53 (TP53 or P53), within the context of several human leukocyte antigens. P53 is the archetypal tumor suppressor gene and the most frequently mutated gene in cancer. Contemporary estimates suggest that >50% of all tumors carry mutations in P53. Because of its prevalence in cancer and its restricted expression to precancerous and cancerous cells, this antigen may be targeted on mutant P53-expressing tumors with minimal normal tissue toxicity.